Education
About Us
Working with TipRanks
Follow Us
uniQure N.V. (QURE)
NASDAQ:QURE
Top Page
uniQure
(NASDAQ:QURE)
Select Model
Select Model
Rating:54Neutral
Price Target:
$48.00
▲(1.05% Upside)
uniQure's overall stock score reflects significant financial challenges, with declining revenues and a weak balance sheet being major concerns. Despite these issues, the stock shows positive technical momentum, and the company has made notable clinical advancements, particularly with AMT-130. However, the negative P/E ratio and lack of dividend yield limit its valuation appeal.
Positive Factors
Clinical Advancements
The successful AMT-130 trial represents a significant step forward in treating Huntington's disease, potentially leading to a first-in-class therapy. This advancement strengthens uniQure's position in the gene therapy market and could drive future revenue growth through new product offerings.
Regulatory Progress
The FDA's breakthrough therapy designation for AMT-130 accelerates its development and review process, enhancing uniQure's competitive edge. This regulatory milestone could expedite market entry, providing a strategic advantage in the gene therapy sector.
Strong Cash Position
A robust cash position provides uniQure with the financial flexibility to fund ongoing R&D and commercialization efforts. This financial stability supports long-term strategic initiatives and mitigates risks associated with cash flow challenges.
Negative Factors
Revenue Decline
The sharp decline in revenue highlights challenges in sustaining sales growth, potentially impacting future profitability. This trend underscores the need for successful commercialization of new therapies to offset revenue losses.
High R&D Expenses
Rising R&D expenses reflect increased investment in pipeline development, which, while necessary for innovation, pressures margins. Sustained high R&D costs without corresponding revenue growth could strain financial resources over time.
Weak Balance Sheet
A weak balance sheet with negative equity and high leverage raises concerns about financial stability. This precarious position could limit uniQure's ability to finance new projects or weather economic downturns, impacting long-term viability.
uniQure (QURE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$758.81M
Dividend YieldN/A
Average Volume (3M)1.15M
Price to Earnings (P/E)―
Beta (1Y)1.57
Revenue Growth-48.25%
EPS Growth33.77%
CountryUS
Employees209
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.69
Shares Outstanding54,866,930
10 Day Avg. Volume1,520,880
30 Day Avg. Volume1,154,577
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue63.40
Enterprise Value/Gross Profit76.75
Enterprise Value/Ebitda-6.25
Forecast
1Y Price Target
$69.00Price Target Upside45.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
uniQure Business Overview & Revenue Model
Company DescriptionuniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
How the Company Makes MoneyuniQure generates revenue primarily through the commercialization of its gene therapy products, which include marketed products like Zynteglo for beta-thalassemia and other pipeline therapies in late-stage clinical development. The company also earns revenue from research collaborations and licensing agreements with pharmaceutical and biotechnology companies. These partnerships may include upfront payments, milestone payments based on the achievement of specific developmental or regulatory goals, and royalties on future sales of licensed products. Additionally, uniQure may benefit financially from government grants and funding aimed at supporting innovative research in gene therapy.
uniQure Key Performance Indicators (KPIs)
Any
Revenue by Segment
Highlights income from different business areas, offering insight into which segments drive growth and profitability, and where there might be opportunities or challenges.
Highlights income from different business areas, offering insight into which segments drive growth and profitability, and where there might be opportunities or challenges.
Data provided by:
Main Street Data
Main Street DatauniQure Earnings Call Summary
Earnings Call Date:Jul 29, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Oct 29, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant regulatory and clinical advancements, particularly with AMT-130 and AMT-260, and a strong financial position. However, these positives were tempered by a notable decline in revenue and increased R&D expenses.Q2-2025 Updates
Positive Updates
Regulatory Progress for AMT-130
AMT-130 received breakthrough therapy designation from the FDA and achieved alignment on statistical analysis and CMC requirements for a BLA submission in early 2026.
Significant Clinical Advances
The company reported a 92% reduction in seizure frequency with AMT-260 for epilepsy and is on track for pivotal data releases for both AMT-130 and AMT-191 in Fabry disease.
Strong Financial Position
uniQure's cash, cash equivalents, and investment securities totaled $377 million as of June 30, 2025, providing funding into the second half of 2027.
Negative Updates
Revenue Decline
Total revenue for Q2 2025 was $5.3 million, a decrease from $11.1 million in the same period of 2024, primarily due to decreases in collaboration and contract manufacturing revenues.
Research and Development Expenses
R&D expenses increased to $35.4 million, up from $33.7 million in the same period of 2024, due to higher external program spend and increased fair value of contingent consideration.
Company Guidance
During the second quarter of 2025 earnings call, uniQure provided detailed guidance on their ongoing clinical advancements and regulatory progress, with a particular focus on AMT-130, a potential first disease-modifying therapy for Huntington's disease. Key metrics shared included the breakthrough therapy designation granted by the FDA in April, alignment with the FDA on the statistical analysis plan and CMC requirements, and the planned BLA submission in Q1 2026. The primary efficacy analysis will use a 3-year change in cUHDRS comparing high-dose patients to a propensity score matched external control. The company also reported an ongoing PPQ campaign and commercial launch preparations for 2026. Revenue for Q2 2025 was $5.3 million, a decrease from $11.1 million in the same period in 2024, with research and development expenses at $35.4 million. Cash, cash equivalents, and investment securities totaled $377 million as of June 30, 2025, positioning the company well for its planned commercialization efforts.uniQure Financial Statement Overview
Summary
uniQure is facing significant financial challenges with declining revenues, negative profit margins, and a weak balance sheet. The company's high debt levels and negative equity position raise concerns about its financial stability. While there is a slight improvement in free cash flow, the overall financial health of the company is precarious, requiring strategic interventions to improve profitability and strengthen the balance sheet.Income Statement
uniQure's income statement reflects significant challenges with declining revenues and negative profit margins. The TTM data shows a sharp revenue decline of 29% and a net profit margin of -13.88%, indicating substantial losses. Despite a high gross profit margin of 82.61% in the TTM, the company struggles with negative EBIT and EBITDA margins, highlighting operational inefficiencies.30
Negative
Balance Sheet
The balance sheet reveals a concerning financial position with negative stockholders' equity and a high debt-to-equity ratio of -16.66 in the TTM. This indicates financial instability and potential solvency issues. The return on equity is also negative, reflecting ongoing losses and poor returns for shareholders.25
Negative
Cash Flow
uniQure's cash flow statement shows a slight improvement in free cash flow growth at 4.33% in the TTM, but the operating cash flow remains negative, indicating cash burn. The free cash flow to net income ratio is slightly above 1, suggesting that the company is generating enough cash to cover its net losses, but the overall cash flow situation remains weak.35
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.34M | 27.12M | 15.84M | 106.48M | 524.00M | 37.51M |
| Gross Profit | 11.84M | 8.79M | 2.21M | 103.14M | 499.03M | -84.89M |
| EBITDA | -145.35M | -160.75M | -253.10M | -108.02M | 319.00M | -126.97M |
| Net Income | -199.00M | -239.56M | -308.48M | -126.79M | 329.59M | -125.02M |
Balance Sheet | ||||||
| Total Assets | 584.89M | 556.54M | 831.69M | 704.96M | 809.18M | 340.39M |
| Cash, Cash Equivalents and Short-Term Investments | 376.97M | 367.52M | 617.89M | 352.84M | 556.26M | 244.93M |
| Total Debt | 66.70M | 66.06M | 138.41M | 142.89M | 135.72M | 71.54M |
| Total Liabilities | 588.89M | 563.29M | 624.02M | 228.96M | 213.40M | 96.49M |
| Stockholders Equity | -4.00M | -6.75M | 207.67M | 476.01M | 595.78M | 243.91M |
Cash Flow | ||||||
| Free Cash Flow | -174.26M | -186.10M | -153.08M | -162.75M | 270.52M | -144.31M |
| Operating Cash Flow | -173.44M | -182.73M | -145.93M | -145.06M | 287.96M | -134.83M |
| Investing Cash Flow | 114.22M | 162.97M | -205.69M | -182.73M | -67.39M | -9.48M |
| Financing Cash Flow | 21.18M | -59.49M | 362.72M | 1.45M | 94.86M | 7.44M |
uniQure Technical Analysis
Positive
47.50
Price Trends
15.86
Positive
15.19
Positive
14.41
Positive
Market Momentum
2.21
Negative
91.01
Negative
30.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QURE, the sentiment is Positive. The current price of 47.5 is above the 20-day moving average (MA) of 17.57, above the 50-day MA of 15.86, and above the 200-day MA of 14.41, indicating a bullish trend. The MACD of 2.21 indicates Negative momentum. The RSI at 91.01 is Negative, neither overbought nor oversold. The STOCH value of 30.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QURE.
uniQure Risk Analysis
uniQure disclosed 65 risk factors in its most recent earnings report. uniQure reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
uniQure Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | 1.21B | 5.90 | 33.02% | ― | 799.36% | ― | |
58 Neutral | 1.91B | -3.79 | -59.52% | ― | 14.99% | 14.42% | |
54 Neutral | $758.81M | ― | -427.47% | ― | -48.25% | 33.77% | |
50 Neutral | 703.71M | -7.53 | ― | ― | 2190.50% | 52.85% | |
43 Neutral | 1.03B | -5.57 | ― | ― | ― | -429.68% | |
40 Underperform | 358.24M | -1.33 | ― | ― | ― | 10.36% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
QURE
uniQure
47.50
42.52
853.82%
RCKT
Rocket Pharmaceuticals
3.32
-14.28
-81.14%
SYRE
Spyre Therapeutics
17.00
-12.06
-41.50%
NTLA
Intellia Therapeutics
17.76
-2.81
-13.66%
CVAC
CureVac
5.36
2.34
77.48%
DAWN
Day One Biopharmaceuticals
6.87
-7.42
-51.92%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.